Scarica l'app Stockscreener
54.29
3.59%
1.88
Dopo l'orario di chiusura:
54.57
0.28
+0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Assessing Bristol Myers Squibb After 16% Rally and New Drug Approvals in 2025 - simplywall.st
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Why Bristol-Myers Squibb (BMY) Stock Is Up Today - Finviz
Bristol-Myers Squibb Pops As BofA Upgrades Its Outlook - Finimize
Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says - marketscreener.com
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock? - Finviz
Bristol-Myers Squibb stock rating upgraded to Buy at BofA on pipeline strength - Investing.com
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions - Markets Financial Content
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More - AOL.com
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | - GuruFocus
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Pitcairn Co. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Checkpoint Inhibitors Market Is Going to Boom |Bristol-Myers Squibb • Merck & Co. - openPR.com
Caldwell Trust Co Makes New $1.70 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More - AOL.com
Bristol-Myers Squibb Shares Gain Momentum from Regulatory Advances - AD HOC NEWS
Buoyed by BMS milestones, Orum moves to build in-house clinical muscle - koreabiomed.com
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Coppell Advisory Solutions LLC Makes New $1.90 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Birchview Capital LP Has $14.97 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by AQR Capital Management LLC - MarketBeat
BMY Stock Rises: Analyst Upgrade to Buy & Opdivo FDA Priority Review | Dec 12, 2025News and Statistics - IndexBox
Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review - Oncodaily
Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? - Yahoo Finance
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street's 2026 Focus - ts2.tech
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum? - Yahoo Finance
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News - GuruFocus
Peapack Gladstone Financial Corp Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications - BioSpace
How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates - Yahoo Finance
BNP Paribas Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application - pharmiweb.com
Bristol Myers Squibb (BMY) Seeks FDA Approval for Expanded Opdiv - GuruFocus
Bristol Myers wins FDA priority review for Opdivo in first-line Hodgkin lymphoma - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Featured in Sector Research Coverage - Kalkine Media
Nathan Pennell: Proud of Bristol Myers Squibb Team Presenting at ASH25 - Oncodaily
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma - Yahoo Finance
Bristol-Myers Squibb’s Strategic Moves: A Dual Focus on Shareholder Returns and Oncology Expansion - Ad-hoc-news.de
Bristol Myers (BMY) Declares Increased Quarterly Dividend for 20 - GuruFocus
Bristol Myers Squibb raises quarterly dividend by 1.6% - Investing.com Nigeria
Bristol-Myers Squibb Raises Quarterly Dividend by 1.6% to $0.63 a Share, Payable on Feb. 2, 2026 to Shareholders of Record on Jan. 2, 2026 - marketscreener.com
Bristol Myers Squibb Announces Dividend Increase - marketscreener.com
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) t - GuruFocus
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating - marketscreener.com
Peering Into Bristol-Myers Squibb Co's Recent Short Interest - Sahm
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound - Yahoo Finance
BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer - Citeline News & Insights
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
Bristol Myers Squibb Company $BMY Shares Bought by Investment Management Corp of Ontario - MarketBeat
BioNTech, Bristol Myers presents Phase 2 data for PD-L1xVEGF-A - TipRanks
66,361 Shares in Bristol Myers Squibb Company $BMY Bought by SVB Wealth LLC - MarketBeat
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - The Manila Times
Bristol Myers Squibb Company $BMY Stock Position Raised by Axa S.A. - MarketBeat
Analysts Project Modest Upside To Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb (BMY) Is Up 5.1% After Expanded Breyanzi MZL Approval Has The Bull Case Changed? - simplywall.st
Bristol Myers Squibb showcases new lymphoma therapy data at ASH meeting - Investing.com Canada
1.77%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):